Dark

Check out our Dark Pool Levels

CFRX
CONTRAFECT CORP
stock OTC

Inactive

Dec 5, 2023

0.0500USD-27.954%(-0.0194)910,216

Pre-market

0.00USD-100.000%(-0.07)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

04:21PM EST ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis Benzinga

04:05PM EST ContraFect Announces Award from the Cystic Fibrosis Foundation to GlobeNewswire Inc

Dec 20, 2021

09:00AM EST Compassionate Use Case Study Demonstrating the Potential of GlobeNewswire Inc

Dec 9, 2021

09:59PM EST From Benzinga's Global Small Cap Conference: ContraFect President & CEO, Roger J. Pomerantz, M.D., F.A.C.P. Begins Presenting Benzinga

Dec 5, 2021

06:11AM EST CFRX: Direct Lytic Agents Show In Vitro Activity Against Gram-Negative Pathogens Benzinga

Nov 15, 2021

10:57AM EST ContraFect Q3 EPS $(0.13) Up From $(0.19) YoY Benzinga

07:30AM EST ContraFect Reports Third Quarter 2021 Financial Results and GlobeNewswire Inc

Nov 9, 2021

11:36AM EST ContraFect's New Data Presented At NACFC Demonstrate Potential Of Direct Lytic Agents To Treat Pulmonary Infections In Patients With Cystic Fibrosis Benzinga

07:30AM EST ContraFects New Data Presented at NACFC GlobeNewswire Inc

Oct 26, 2021

07:45AM EDT ContraFect To Present Data On The Potential Of DLAs To Treat Pulmonary Infections In Cystic Fibrosis Patients Nov. 2 Benzinga

07:30AM EDT ContraFect to Present Data on the Potential of DLAs to Treat GlobeNewswire Inc

Oct 17, 2021

06:41AM EDT CFRX: New Data on Exebacase Shows Rapid Resolution of Symptoms in Phase 2 Trial Benzinga

Oct 13, 2021

03:38PM EDT ContraFect Shares Move Higher On Spike In Volume, Co. Receives Notice Of Allowance For U.S. Patent Application Titled 'ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION, AND COMPOSITIONS, COMBINATIONS AND METHODS FOR USE THEREOF' Benzinga

Oct 4, 2021

09:11AM EDT ContraFect Highlights Presentation Of Phase 2 Exebacase Data At IDWeek Benzinga

09:00AM EDT ContraFects New Phase 2 Exebacase Data Presented GlobeNewswire Inc

Sep 29, 2021

07:33AM EDT ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek 2021 Sept. 29 Through Oct. 3 Benzinga

07:30AM EDT ContraFect to Present New Late Breaking Phase 2 Exebacase Data on GlobeNewswire Inc

Sep 22, 2021

07:30AM EDT ContraFect Corporation to Present at the 2021 Cantor Global GlobeNewswire Inc

Sep 9, 2021

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

06:50AM EDT SVB Leerink Initiates Coverage On ContraFect with Outperform Rating, Announces Price Target of $14 Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

08:10AM EDT ContraFect Q2 Net Loss $5.4 Mln Or $0.14/Shr Vs Loss Of $17.6 Mln Or $0.88/Shr Last Year RTTNews

07:35AM EDT ContraFect Q2 EPS $(0.14) Up From $(0.88) YoY Benzinga

07:30AM EDT Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Companys DLA portfolio GlobeNewswire Inc

Jul 31, 2021

06:01AM EDT CFRX: Presentations at ECCMID Highlight Advances in Lysin Benzinga

Jul 19, 2021

11:08AM EDT UPDATE: ContraFect Posts Presentation For European Congress Of Clinical Microbiology, Infectious Diseases Segment 'Synergistic anti-biofilm activity ofexebacase and rifampin, vancomycin or daptomycin against Staphylococcus...' Benzinga

07:33AM EDT ContraFect Highlights Publications On CF-296 Benzinga

07:31AM EDT ContraFect Announces Multiple Presentations of New Research Data GlobeNewswire Inc

07:30AM EDT ContraFect Announces Multiple Publications on CF-296 Demonstrating GlobeNewswire Inc

Jun 17, 2021

07:31AM EDT ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President GlobeNewswire Inc

07:30AM EDT ContraFect Invited to Present New Research Data From Its Pipeline GlobeNewswire Inc

May 26, 2021

07:30AM EDT Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function GlobeNewswire Inc

May 24, 2021

12:21PM EDT CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial in Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

07:32AM EDT ContraFect Q1 EPS $(0.18) Up From $(0.49) YoY Benzinga

07:30AM EDT Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 GlobeNewswire Inc

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 3, 2021

07:30AM EDT ContraFect Announces Issuance of Composition of Matter Patent for GlobeNewswire Inc

Apr 27, 2021

11:06AM EDT ContraFect Awarded U.S. Patent Titled 'Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof' Benzinga

Apr 26, 2021

07:30AM EDT ContraFect Invited to Participate in the Cystic Fibrosis Target GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 15, 2021

06:30PM EDT ContraFect Invited to Present at the Inaugural Anti-Infectives GlobeNewswire Inc

Apr 14, 2021

07:11AM EDT CFRX: Raises $53.7 Million in Public Offering Benzinga

Apr 8, 2021

08:14AM EDT The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data Benzinga

Mar 31, 2021

10:02AM EDT WBB Securities Initiates Coverage On ContraFect with Speculative Buy Rating, Announces Price Target of $6.5 Benzinga

Mar 30, 2021

07:38AM EDT ContraFect Q4 EPS $(0.23) Up From $(1.11) YoY Benzinga

07:30AM EDT Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 GlobeNewswire Inc

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 22, 2021

04:05PM EDT ContraFect Corporation Announces Closing of Public Offering and GlobeNewswire Inc

Mar 18, 2021

02:32PM EDT Mid-Afternoon Market Update: Nasdaq Down 2%; Williams-Sonoma Shares Jump On Upbeat Earnings Benzinga

12:04PM EDT Mid-Day Market Update: Crude Oil Down 4%; Upstart Shares Spike Higher Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Down; Dollar General Profit Misses Estimates Benzinga

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 17, 2021

11:27PM EDT ContraFect Prices Underwritten Public Offering Of 10 Mln Shares At $5.00/shr RTTNews

11:00PM EDT ContraFect Corporation Prices Public Offering of Common Stock GlobeNewswire Inc

04:01PM EDT ContraFect Reports Common Stock Offering, No Size Disclosed Benzinga

04:01PM EDT ContraFect Corporation Announces Proposed Public Offering of GlobeNewswire Inc

Mar 12, 2021

01:13PM EST ContraFect shares were trading higher after the company announced it was awarded a BARDA contract for up to $86.8 million. Benzinga

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

04:13PM EST ContraFect Sees Results From Phase 3 DISRUPT Study Interim Analysis In H2'2021 Benzinga

04:12PM EST ContraFect Reports $86.8M Biomedical Advanced Research and Development Authority (BARDA) Contract Win Benzinga

04:05PM EST BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections GlobeNewswire Inc

09:54AM EST Contrafect Shares Move Higher As Traders Circulate Federal Procurement Data System Doc For $9.7M Health & Human Services Contract By Co. For Development Of Exebacase For Treatment Of Bloodstream Infections Benzinga

Feb 11, 2021

07:00AM EST ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Jane F. Barlow, MD, MPH, MBA to the Companys board of directors (Board). GlobeNewswire Inc

Nov 13, 2020

08:35AM EST ContraFect Q3 EPS $(0.19) Down From $(0.07) YoY Benzinga

08:33AM EST CARB-X and Cystic Fibrosis Foundation grantsprovide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections GlobeNewswire Inc

Oct 26, 2020

07:02AM EDT ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients Benzinga

07:00AM EDT ContraFect Initiates Expanded Access to Exebacase for the GlobeNewswire Inc

Sep 9, 2020

07:30AM EDT ContraFect to Present at the 2020 Cantor Global Virtual Healthcare GlobeNewswire Inc

Aug 25, 2020

07:30AM EDT ContraFect Announces Funding Agreement with the Cystic Fibrosis GlobeNewswire Inc

Aug 14, 2020

07:36AM EDT ContraFect Q2 EPS $(0.88) Down From $(0.11) YoY Benzinga

07:30AM EDT Exebacase Phase 2 study results published in the Journal of Clinical Investigation GlobeNewswire Inc

Jul 20, 2020

07:35AM EDT ContraFect Announces Up To $18.9M In Funding From CARB-X To Support Acceleration Of CF-370 Program For Treating Pseudomonas Aeruginosa Infections Towards Clinical Stage Development Benzinga

07:30AM EDT ContraFect Announces up to $18.9 Million in Funding from CARB-X to GlobeNewswire Inc

Share